UNIKUM Therapeutics ApS: Financial statements 2021
CVR: 41192925
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
UNIKUM Therapeutics ApS (CVR 41192925) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK -2,726,200 and a net result of DKK -5,555,369 compared with DKK -2,132,103 the year before. Equity in the 2021 report amounted to DKK -7,645,367. The company had 5 employees in the financial year.
- Gross Profit
- DKK -2,726,200
- Profit/Loss
- DKK -5,555,369
- Equity
- DKK -7,645,367
- Total Assets
- DKK 6,700,128
- Employees
- 5
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | -2.7M | -5.6M | -7.6M | 5 |
| 2020 | - | -1.1M | -2.1M | -2.1M | 2 |
Official annual report
Find more companies like UNIKUM Therapeutics ApS
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2021
UNIKUM Therapeutics ApS has published its interim report for the period February 17, 2020 to December 31, 2020.
As of April 1, 2021, Rasmus Otkjær Bak is registered as director of UNIKUM Therapeutics ApS.
As of April 1, 2021, Søren Sylvester Skjærbæk has stepped down as director of UNIKUM Therapeutics ApS.
About UNIKUM Therapeutics ApS
UNIKUM Therapeutics ApS is a Danish company of the type Anpartsselskab based in Risskov, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Martin Roelsgaard Jakobsen. The board consists of Ulrik Bjerl Nielsen (chair), Martin Roelsgaard Jakobsen and Stefan Wildt. The company's owners include MEDIC ADVICE ApS, MR Jakobsen Holding ApS and BII Holdings A/S. The company has 2 employees (2025). In 2025, the company reported a gross profit of DKK -247,887 and a net result of DKK -859,076 compared with DKK -13,797,011 the year before. Equity in the 2025 report amounted to DKK -5,680,033.
